Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.56 |
| ▸ | REN | P00797 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PEPD | P12955 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405754 | 1.00 | ACE (0.56) | ACERENKDM4EF2LMNA | |
| SCHEMBL29615543 | 0.95 | ACE (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL6681470 | 0.94 | ACE (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL6681472 | 0.94 | ACE (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL30899064 | 0.94 | ACE (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL30203686 | 0.87 | DPP4 (0.44) | ACERENKDM4EF2LMNA | |
| SCHEMBL2739551 | 0.87 | ACE (0.56) | ACERENKDM4EF2LMNA | |
| SCHEMBL30452048 | 0.87 | CAPN1 (0.48) | ACERENKDM4EF2LMNA | |
| SCHEMBL11331490 | 0.85 | ACE (0.68) | ACERENKDM4EF2LMNA | |
| SCHEMBL757253 | 0.85 | ACE (0.68) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | L'OREAL (FR) | 2026-03-05 | — | — | US | claimed |
| US-12317911-B2 | Flavor compositions and screening methods for identifying the same | MARS, INCORPORATED (US) | 2025-06-03 | — | — | US | claimed |
| EP-4499661-A1 | COMPOUND - DIAGNOSTIC MARKER FOR INTESTINAL CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF INTESTINAL CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF INTESTINAL CANCER | Urteste S.A. (PL) | 2025-02-05 | — | — | EP | claimed |
| CN-116008370-B | Anti-pollution electrochemical immunosensor based on PEG-polypeptide conjugate, and preparation method and application thereof | 青岛科技大学 | 2024-11-15 | — | — | CN | claimed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| US-20240165006-A1 | DERMATOLOGICAL COMPOSTIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2024-05-23 | — | — | US | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| EP-4349412-A2 | METHODS FOR DETERMINING AND ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS IN TREATMENT OF CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-04-10 | — | — | EP | claimed |
| CN-114124738-B | Cloud environment service fault probability calculation method, system and terminal based on service interaction diagram | 昆明理工大学 | 2024-03-19 | — | — | CN | claimed |
| CN-117603309-A | Peptides for the treatment of cancer and uses thereof | 主流源生物科技(上海)有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-110732018-B | Preparation method of tuna meat ACE inhibitory peptide chewable tablets | 浙江海洋大学 | 2023-04-07 | — | — | CN | claimed |
| EP-4125993-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF | Bone Sci. Bio Ltd. (IL) | 2023-02-08 | — | — | EP | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| WO-2022257479-A1 | FUSION PROTEIN FOR TREATING METABOLIC DISEASES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江南大学 | 2022-12-15 | — | — | WO | claimed |
| WO-2022227707-A1 | PREPARATION METHOD FOR AND APPLICATION OF DOUBLE-TARGET FUSION PROTEIN | 江南大学 | 2022-11-03 | — | — | WO | claimed |
| WO-2022201146-A1 | DERMATOLOGICAL COMPOSITIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2022-09-29 | — | — | WO | claimed |
| WO-2022181712-A1 | COMPOSITION CONTAINING DECOMPOSED PRODUCTS OF VEGETABLE PROTEIN AND METHOD FOR PRODUCING SAME | 株式会社Mizkan Holdings | 2022-09-01 | — | — | WO | claimed |
| CN-114656524-A | Targeted ovarian polypeptide and application thereof | 深圳先进技术研究院 | 2022-06-24 | — | — | CN | claimed |
| WO-2022074228-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2022-04-14 | — | — | WO | claimed |
| CN-114124738-A | Cloud environment service fault probability calculation method, system and terminal based on service interaction graph | 昆明理工大学 | 2022-03-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | TYR, CUTA, ARGLU1 | ACE 3524/4885REN 1937/4885KDM4E 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.